We are thrilled to announce the signing of an over-arching agreement with the University of Dundee and their Drug Discovery Unit (DDU) to access research relating to novel therapeutic candidates.

The first Evaluation Agreement under the framework focuses on investigating a lead series of therapeutic candidates in the increasingly important research area of pro-senescence (selectively promoting ageing of cancer cells to cease growth in tumours). This exciting area of research has the potential to be effective in treating multiple cancer types, and also many other disease areas, including those associated with healthy ageing.

This work builds upon previous ground-breaking research by Dundee and Barts Charity funded research by Prof Cleo Bishop, Professor of Senescence and Director of the Queen Mary University London Phenotypic Screening Facility.

Speaking about the agreement, ValiRx CEO Dr Suzy Dilly said:

"We are delighted to be able to streamline the process of reviewing and accessing the excellent research from the University of Dundee's DDU, which will help to bring on evaluation projects more quickly."

Professor David Gray, Head of Biology and innovative targets portfolio lead at the DDU commented:

"We are delighted that our UKRI Impact Accelerator Award has enabled us to translate the groundbreaking work of our collaborator Cleo Bishop at Queen Mary University London, to the point where ValiRx see the potential for treating patients."

Watch the announcement video, recorded by BRR Media, where ValiRx CSO Dr Cathy Tralau Stewart explains the agreement in more detail.

Click here to watch the video with ValiRx CSO, Dr Cathy Tralau-Stewart.